Prodrugs of 4′-demethyl-4-deoxypodophyllotoxin: Synthesis and evaluation of the antitumor activity

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 23, 2002, Pages 3435-3438

  Kim, Yong ^a   You, Young Jae ^a   Nam, Nguyen Hai ^a   Ahn, Byung Zun ^a  

^a Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROETHYLOXYCARBONYL 4' NORPODOPHYLLOTOXIN; 2 HYDROXYETHYLCARBAMOYL 4' NORPODOPHYLLOTOXIN; 4' NORPODOPHYLLOTOXIN; AMINO ACID DERIVATIVE; CARBAMIC ACID DERIVATIVE; CARBONIC ACID DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; AMINO ACID; ANTINEOPLASTIC AGENT; DEOXYPODOPHYLLOTOXIN; DRUG DERIVATIVE; PODOPHYLLOTOXIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; CELL CULTURE; CHEMISTRY; HYDROLYSIS; LD 50; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; CARBAMATES; CARBONATES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROLYSIS; LETHAL DOSE 50; PODOPHYLLOTOXIN; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0036888356     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00758-8     Document Type: Article

References (17)

1. Noguchi T., Kawanami M. Yakugaku Zasshi. 60:1940;629.
2. King L.S., Sullivan M.S. Science. 104:1946;244.
3. Gensler W.J., Murthy C.A., Tranneli M.H. J. Med. Chem. 20:1977:635.
4. Loike D., Brewer G.F., Streniicht H., Gensler W.J., Horwitz S.B. Cancer Res. 38:1978:2688.
5. Gensler W.J., Murthy C.A., Tranneli M.H. J. Med. Chem. 20:1977;635 Loike D., Brewer G.F., Streniicht H., Gensler W.J., Horwitz S.B. Cancer Res. 38:1978;2688 Stahelin H., Wartburg A. Progress Drug Res. 33:1989;169.
6. Kim Y., You Y.J., Kim S.B., Ahn B.Z. Planta Med. 68:2001;271.
7. Terada T., Fujimoto K., Nomura M., Yamashita J., Kobunai T., Takeda S., Wierzba K., Yamada Y., Yamaguchi H. Chem. Pharm. Bull. 40:1992;2720.
8. Kozawa M., Baba K., Matsuyama Y., Kido T., Sakai M., Takemoto T. Chem. Pharm. Bull. 30:1982;2885.
9. Laurent D., Yves G., Demerseman P., Kruczynski A., Etievant C., Imbert T., Hill B.T., Monneret C. J. Med. Chem. 41:1998;4475.
10. 8: C, 65.18; H, 6.28; N, 2.82; found: C, 65.00; H, 6.22; N, 2.79.
11. Water solubility was measured by a method described in literature: Itoh M., Hagiwara D., Kamiya T. Bull. Chem. Soc. Jpn. 50:1977;718.
12. Ohisumi K., Hatanaka T., Nakagawa R., Fukuda Y., Morinaga Y., Suga Y., Nihei Y., Ohishi K., Akiyama Y., Tsuji T. Anti-Cancer Drug Des. 14:1999;539.
13. Olsson O.A.T., Svensson L.A. Pharm. Res. 1:1984;19.
14. Thorberg S.O., Berg S., Lundstorm J., Pettersson B., Wijkstorm A., Sanchez D., Lindberg P., Nilsson J.L.G. J. Med. Chem. 30:1987;2008.
15. Vlieghe P., Bihel F., Clerc T., Pannecouque C., Witvrouw M., Erik D.C., Salles J.P., Chermann J.C., Kraus J.L. J. Med. Chem. 44:2001;777.
16. Cytotoxicity was determined by a method described previously. Skehan P., Storeng R., Scudiero D., Monk A., MacMahon J., Vistica D., Warren J., Bokesch H., Kenny S., Boyd M.R. J. Nat. Cancer Inst. 82:1990;1107.
17. 2)/2, where L and W represent the length and the width of the tumor mass, respectively. The inhibition rate (IR) was calculated according to the following formula: IR (%)=[(mean TV of the control group-mean TV of the treated group)/mean TV of the control group]×100.